首页|Dominant negative TGF-β receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses
Dominant negative TGF-β receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Transforming growth factor-β (TGF-β) is a multifunctional regulatory cytokine that maintains tolerance in the immune system by regulating the proliferation， differentiation and survival of lymphocytes。 TGF-β blockade therapy for cancer has achieved some results but shows limited efficacy and side effects because these drugs are not selective and act on various types of cells throughout the body。 We demonstrate here that dominant negative TGF-β receptor type II specifically targeting T cells decreases tumor load in tumor-bearing mice。 In addition， the dominant negative TGF-β receptor type II promotes the proliferation and differentiation of T cells and increases the expression of T-bet， which in turn promotes the secretion of granzyme A， granzyme B， perforin and IFN-γ secreted by T cells， and enhances the cytotoxicity and anti-tumor effects of T cells。 Moreover， we also found that dominant negative TGF-β receptor type II reduces the proportion of regulatory T cells (Tregs) in tumor tissue and spleen of tumor-bearing mice。 Co-culture experiments with T cells and tumor cells revealed that dominant negative TGF-β receptor type II inhibited tumor cell proliferation and increased apoptosis。 Our results indicate that specifically inhibiting TGF-β receptor type II in T cells increases anti-tumor immunity and has a strong therapeutic potential。
NSTL
